An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Amrubicin; Topotecan; Topotecan
Indications Small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms CheckMate 331
Sponsors Bristol-Myers Squibb; Ono Pharmaceutical

Most Recent Events

18 Sep 2022 This trial has been completed in Hungary, according to European Clinical Trials Database record (22 Aug 2022).
16 Sep 2022 Status changed from active, no longer recruiting to completed.
09 Feb 2022 Planned End Date changed from 28 Jan 2022 to 30 May 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight